|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 16/28 | |
| A61K 39/395 | |||
| A61P 35/02 |
| (11) | Number of the document | 3066129 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14803293.1 |
| Date of filing the European patent application | 2014-11-06 | |
| (97) | Date of publication of the European application | 2016-09-14 |
| (45) | Date of publication and mention of the grant of the patent | 2019-06-19 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2014/064320 |
| Date | 2014-11-06 |
| (87) | Number | WO 2015/069874 |
| Date | 2015-05-14 |
| (30) | Number | Date | Country code |
| 201361900898 P | 2013-11-06 | US |
| (72) |
GHOBRIAL, Irene M., US
ROCCARO, Aldo M., US
CARDARELLI, Josephine M., US
SACCO, Antonio, US
|
| (73) |
Bristol-Myers Squibb Company,
Route 206 and Province Line Road, Princeton, NJ 08543,
US
Dana-Farber Cancer Institute, Inc., 450 Brookline Avenue, Boston, MA 02215, US |
| (54) | TREATMENT OF C1013G/CXCR4-ASSOCIATED WALDENSTRÖM`S MACROGLOBULINEMIA WITH AN ANTI-CXCR4 ANTIBODY |
| TREATMENT OF C1013G/CXCR4-ASSOCIATED WALDENSTRÖM`S MACROGLOBULINEMIA WITH AN ANTI-CXCR4 ANTIBODY |